Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study - 26/09/12
, Johannes Schueller, MD b, Ute Heubrandtner, MPharm c, Fritz Wrba, MD e, Dietmar Tamandl, MD f, Klaus Kaczirek, MD f, Rudolf Roka, MD d, Sandra Freimann-Pircher, MPharm c, Thomas Gruenberger, MD fSummary |
Background |
Patients with biliary tract cancer have a poor prognosis, and, until recently, no standard palliative chemotherapy has been defined. We aimed to investigate the efficacy and safety of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) for first-line treatment of biliary tract cancer.
Methods |
From Oct 1, 2006, to July 26, 2008, patients with unresectable locally advanced or metastatic biliary tract cancer were sequentially enrolled and treated at one centre in Austria. All patients received intravenous infusions of 500 mg/m2 cetuximab on day 1, 1000 mg/m2 gemcitabine on day 1, and 100 mg/m2 oxaliplatin on day 2, every 2 weeks for 12 cycles. The primary outcome was overall response rate. Analysis was by intention to treat. Adverse reactions were assessed according to National Cancer Institute Common Toxicity Criteria. The study is completed and registered with ClinicalTrials.gov, number NCT01216345.
Findings |
30 patients with median age of 68 years (IQR 62–73) were enrolled and included in the analysis. Objective response occurred in 19 patients (63%; 95% CI 56·2–69·8), of whom three (10%; 3·2–16·8) achieved complete response, and 16 (53%; 46·2–59·8) achieved partial response. Nine patients underwent potentially curative secondary resection after major response to therapy. Grade 3 adverse events were recorded in 13 patients: skin rash (n=4), peripheral neuropathy (n=4), thrombocytopenia (n=3), nausea (n=1), diarrhoea (n=1), and neutropenia (n=1); no grade 4 adverse events were recorded.
Interpretation |
Cetuximab plus GEMOX was well tolerated and had encouraging antitumour activity, leading to secondary resection in a third of patients. These findings warrant further study of cetuximab plus GEMOX in a large randomised trial.
Funding |
Association of Research on the Biology of Liver Tumors, Vienna, Austria.
Le texte complet de cet article est disponible en PDF.Plan
Vol 11 - N° 12
P. 1142-1148 - décembre 2010 Retour au numéro
Article précédent
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- Jack Cuzick, Ivana Sestak, Michael Baum, Aman Buzdar, Anthony Howell, Mitch Dowsett, John F Forbes, on behalf of the ATAC/LATTE investigators
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- Wyndham H Wilson, Owen A O’Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, John P Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi-Lin Chiu, Yue Cui, Todd Busman, Steven W Elmore, Saul H Rosenberg, Andrew P Krivoshik, Sari H Enschede, Rod A Humerickhouse
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?